Cross-reactive immunity to clade 2 strains of influenza virus a subtype H5N1 induced in adults and elderly patients by fluval, a prototype pandemic influenza virus vaccine derived by reverse genetics, formulated with a phosphate adjuvant, and directed to clade 1 strains

Clinical and Vaccine Immunology

Volumn 16, Issue 4, 2009, Pages 437-443

  Fazekas, György ^a   Martosne Mendi, Rita ^a   Jankovics, Istvan ^b   Szilvasy, Istvan ^c   Vajo, Zoltan ^c  

^a Omninvest Ltd Pilisborosjeno   (Hungary)

^b National Institute of Epidemiology   (Hungary)

^c State Health Center   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM PHOSPHATE; FLUVAL AB; INFLUENZA VACCINE; UNCLASSIFIED DRUG;

ACTIVE IMMUNIZATION; ADULT; AGED; ANTIBODY TITER; ANTIGEN STRUCTURE; ARTICLE; CLADISTICS; CLINICAL TRIAL; CONTROLLED STUDY; CROSS REACTION; DRUG FORMULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETIC TRAIT; HEMAGGLUTINATION INHIBITION; HUMAN; HUMAN EXPERIMENT; IMMUNOGENICITY; INFLUENZA; INFLUENZA VIRUS A H5N1; MORBIDITY; MORTALITY; NORMAL HUMAN; PANDEMIC; PRIORITY JOURNAL; VIRAL GENETICS; VIRUS ISOLATION; VIRUS STRAIN; VIRUS TRANSMISSION; WILD TYPE;

ADJUVANTS, IMMUNOLOGIC; ADULT; AGED; AGED, 80 AND OVER; ALUMINUM COMPOUNDS; ANTIBODIES, VIRAL; DISEASE OUTBREAKS; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HEMAGGLUTININS, VIRAL; HUMANS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; PHOSPHATES; PHYLOGENY; YOUNG ADULT;

EID: 64549140108     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00327-08     Document Type: Article

References (26)

1. Carrat, F., and A. Flahault. 2007. Influenza vaccine: the challenge of antigenic drift. Vaccine 25:6852-6862.
2. Committee for Proprietary Medicinal Products. 5 April 2004. Guideline on dossier structure and content for pandemic influenza vaccine marketing authorisation application. CPMP/VEG/4717/03. European Agency for the Evaluation of Medicinal Products, London, United Kingdom.
3. Committee for Proprietary Medicinal Products. 12 March 1997. Note for guidance on harmonisation of requirements for influenza vaccines. CPMP/ BWP/214/96. European Agency for the Evaluation of Medicinal Products, London, United Kingdom. http://www.emea.europa.eu/pdfs/human/bwp /021496en.pdf.
4. European Centre for Disease Prevention and Control. March 2007. Technical report. Expert advisory groups on human H5N1 vaccines. Scientific questions. European Centre for Disease Prevention and Control, Stockholm, Sweden. http://ecdc.europa.eu/documents/pdf/Sci%20Questions%20final.pdf.
5. European Directorate for the Quality of Medicines & HealthCare. July 2007. European pharmacopeia, 5th ed., supplement 5.8, p. 3406-3407. CD-ROM. European Directorate for the Quality of Medicines & HealthCare, Strasbourg, France.
6. Ferguson, N. M., D. A. Cummings, C. Fraser, J. C. Cajka, P. C. Cooley, and D. S. Burke. 2006. Strategies for mitigating an influenza pandemic. Nature 442:448-452.
7. Germann, T. C., K. Kadau, I. M. Longini, Jr., and C. A. Macken. 2006. Mitigation strategies for pandemic influenza in the United States. Proc. Natl. Acad. Sci. USA 103:5935-5940.
8. Gioia, C., C. Castilletti, M. Tempestilli, P. Piacentini, L. Bordi, R. Chiap-pini, C. Agrati, S. Squarcione, G. Ippolito, V. Puro, M. R. Capobianchi, and F. Poccia. 2008. Cross-subtype immunity against avian influenza in persons recently vaccinated for influenza. Emerg. Infect. Dis. 14:121-128.
9. Govorkova, E. A., R. J. Webby, J. Humberd, J. P. Seiler, and R. G. Webster. 2006. Immunization with reverse-genetics-produced H5N1 influenza vaccine protects ferrets against homologous and heterologous challenge. J. Infect. Dis. 194:159-167.
10. Ichinohe, T., S. Tamura, A. Kawaguchi, A. Ninomiya, M. Imai, S. Itamura, T. Odagiri, M. Tashiro, H. Takahashi, H. Sawa, W. M. Mitchell, D. R. Strayer, W. A. Carter, J. Chiba, T. Kurata, T. Sata, and H. Hasegawa. 2007. Cross-protection against H5N1 influenza virus infection is afforded by intranasal inoculation with seasonal trivalent inactivated influenza vaccine. J. Infect. Dis. 196:1313-1320.
11. Kandun, I. N., H. Wibisono, E. R. Sedyaningsih, Yusharmen, W. Hadisoedarsuno, W. Purba, H. Santoso, C. Septiawati, E. Tresnaningsih, B. Heriyanto, D. Yuwono, S. Harun, S. Soeroso, S. Giriputra, P. J. Blair, A. Jeremi-jenko, H. Kosasih, S. D. Putnam, G. Samaan, M. Silitonga, K. H. Chan, L. L. Poon, W. Lim, A. Klimov, S. Lindstrom, Y. Guan, R. Donis, J. Katz, N. Cox, M. Peiris, and T. M. Uyeki. 2006. Three Indonesian clusters of H5N1 virus infection in 2005. N. Engl. J. Med. 355:2186-2194.
12. Kendal, A. P., M. S. Pereira, and J. J. Skehel (ed.). 1982. Concepts and procedures for laboratory based influenza surveillance. Centers for Disease Control, Atlanta, GA.
13. Klimov, A., and N. Cox. 2003. Serologic diagnosis of influenza virus infections by hemagglutination inhibition chapter 7, p. 1-5. In Influenza laboratory course. Centers for Disease Control and Prevention, Atlanta, GA.
14. Leroux-Roels, I., A. Borkowski, T. Vanwolleghem, M. Dramé, F. Clement, E. Hons, J. M. Devaster, and G. Leroux-Roels. 2007. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 370:580-589.
15. Lu, X., L. E. Edwards, J. A. Desheva, D. C. Nguyen, A. Rekstin, I. Stephenson, K. Szretter, N. J. Cox, L. G. Rudenko, A. Klimov, and J. M. Katz. 2006. Cross-protective immunity in mice induced by live-attenuated or inactivated vaccines against highly pathogenic influenza A (H5N1) viruses. Vaccine 24:6588-6593.
16. Ninomiya, A., M. Imai, M. Tashiro, and T. Odagiri. 2007. Inactivated influ-enza H5N1 whole-virus vaccine with aluminum adjuvant induces homologous and heterologous protective immunities against lethal challenge with highly pathogenic H5N1 avian influenza viruses in a mouse model. Vaccine 25:3554-3560.
17. Reed, L. J., and H. Muench. 1938. A simple method of estimating fifty per cent endpoints. Am. J. Hyg. 27:493-497.
18. Rowe, T., R A. Abernathy, J. Hu-Primmer, W. W. Thompson, X. Lu, W. Lim, K. Fukuda, N. J. Cox, and J. M. Katz. 1999. Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J. Clin. Microbiol. 37:937-943.
19. Takatsy, G. 1952. Purified precipitated virus obtained by a new simple method. Acta Med. Acad. Sci. Hung. 3:185-191.
20. Tumpey, T. M., M. Renshaw, J. D. Clements, and J. M. Katz. 2001. Mucosal delivery of inactivated influenza vaccine induces B-cell-dependent heterosubtypic cross-protection against lethal influenza A H5N1 virus infection. J. Virol. 75:5141-5150.
21. U.S. Food and Drug Administration. May 2007. Guidance for industry. Clinical data needed to support the licensure of pandemic influenza vaccines. http://www.fda.gov/cber/gdlns/panfluvac.htm.
22. Vajo, Z., L. Kosa, I. Visontay, M. Jankovics, and I. Jankovics. 2007. Inactivated whole virus influenza A (H5N1) vaccine. Emerg. Infect. Dis. 13:807-808. (Letter.)
23. Walls, H. H., M. W. Harmon, J. J. Slagle, C. Stocksdale, and A. P. Kendal. 1986. Characterization and evaluation of monoclonal antibodies developed for typing influenza A and influenza B viruses. J. Clin. Microbiol. 23:240-245.
24. Webster, R. G., and E. A. Govorkova. 2006. H5N1 influenza-continuing evolution and spread. N. Engl. J. Med. 355:2174- 2177.
25. Wood, J. M., G. C. Schild, R. W. Newman, and V. Seagroatt. 1977. An improved single-radial-immunodilfusion technique for the assay of influenza haemagglutinin antigen: application for potency determinations of inactivated whole virus and subunit vaccines. J. Biol. Stand. 5:237-247.
26. World Health Organization Global Influenza Program Surveillance Network. 2005. Evolution of H5N1 avian influenza viruses in Asia. Emerg. Infect. Dis. 11:1515-1521.